Content continues after advertisement

Treatment of Canine Urinary Incontinence (second of 2 parts)

Stefano Romagnoli, DVM, MS, PhD, Diplomate ECAR, University of Padova, Italy

Urology & Nephrology

|December 2007|Peer Reviewed
Print/View PDF

Profile

Definition
Urinary incontinence (UI) is the involuntary loss of urine during the filling phase of the bladder during recumbency and/or standing.

Signalment
• Dogs of any age or sex may present with UI but it is more prevalent in spayed females (accounting for about 80% of adult cases), female dogs spayed prior to 3 months of age, and tail-docked bitches.
• UI is sometimes observed in prepubertal dogs due to congenital conditions.

Causes
Adult Dogs
• Urethral sphincter mechanism incompetence (USMI)-a reduced urethral closure that commonly develops after spaying
• Bladder neoplasia
• Vaginal neoplasia
• Prostatic surgery
• Ureterovaginal fistula
• Acquired neurologic condition
• Chronic urine retention
• Detrusor instability

Prepubertal dogs
• Ureteral ectopia
• Congenital USMI
• Bladder hypoplasia
• Intersex condition
• Pervious urachus
• Congenital neurologic condition

Risk Factors
Previously continent animals
• Gonadectomy
• Prepubertal gonadectomy in females, especially if performed prior to 3 months of age
• Surgery to uterus, prostate, bladder, or urethra
• Tail docking in females

Treatment

Inpatient/Outpatient
UI therapy can be medical, surgical, or a combination of both.

Medical
• In USMI, medication should be the first course of treatment. In animals refractory to medical treatment, surgery may solve the problem or at least reduce drug dependence, which is often a lifelong consideration.
• Pain medication is not usually necessary in UI.

Surgical
• Surgery is the treatment of choice when UI is caused by urogenital tract neoplasia or anatomic defects. A surgical approach includes directly or indirectly correcting the proximal urethra so the bladder neck is within the abdominal cavity and the urethral lumen is somewhat restricted. Techniques include colposuspension, urethropexy, cystourethropexy, transpelvic sling, and, in male dogs, deferentopexy or prostatopexy. Reduction of the urethral lumen can also be achieved through endoscopically injecting collagen under the urethral mucosa.
• Medical treatment should be discontinued before surgery (particularly estrogens, because their long-lasting effects on the reproductive system create a risk for dysuria following surgery).
• Colposuspension is the most popular procedure, while other techniques are used much less frequently. Regardless of surgical approach, approximately 50% of patients are cured, 40% show some improvement, and 10% show no improvement.
• Transient postsurgical dysuria is a common sequela, especially after colposuspension, because the urethra is compressed against the pubic bone or because of vagal stimulation during surgery. It can often be prevented by taking care not to place vaginal sutures too close to the urethra, but if it does occur can be controlled with diazepam (0.2 mg/kg orally 2 to 3 times daily) until normal micturition is regained.
• USMI often improves after puberty, so a decision on surgery should be postponed in prepubertal dogs.

Activity
Suture breakdown can be caused by the passing of large quantities of hard feces or by heavy exercise shortly after surgery. Intestinal contents must be evacuated prior to surgery and heavy exercise, running, or jumping should be avoided for at least 4 weeks following surgery.

Client Education
• UI is often an intermittent disease. A subclinical condition may suddenly become clinical or a latency phase terminated as the result of:
- Fatigue or stress
- Weight gain
- Hot, humid weather
• Management of incontinent animals should include eliminating as much stress as possible and, provided that urine-concentrating capacities are normal as evidenced by hypersthenuric urine-specific gravity and normal urea nitrogen and creatinine concentration in plasma, maintaining a small bladder during periods of recumbency.

Medications
Continence is generally improved following administration of sympathetic/parasympathetic or estrogenic drugs. Efficacy tends to decrease over time despite increasing dosages, perhaps as a result of receptor desensitization. Because of the multifactorial character of this condition, no single treatment will be 100% effective.

Steroids
• Many steroids have been used to treat canine UI, including 17β-estradiol, estradiol benzoate, estradiol valerate, diethylstilbestrol, estriol, conjugated estrogens, and, in male dogs, androgens. Short-acting estrogens such as estriol (characterized by short nuclear occupance time and minimal metabolism following absorption) show equal efficacy with other estrogenic compounds while avoiding estrogenic side effects such as endometrial hyperplasia, pyometra, and bone marrow suppression.
• Estriol is widely used at oral dosages of 0.5 mg/day to 2 mg/day. Its efficacy is approximately 80% to 85% with a fairly quick onset of action (several days).
• Treatment protocols should be started at a high dose (2 mg/day) for 1 week until continence is reached and gradually decreased (ie, 1.5 mg/day on week 2, 1 mg/day on week 3, and 0.5 mg/day on week 4). If the dog is continent on 0.5 mg/day, this dosage can be administered every second day on week 5, every third day on week 6, and weekly on week 7. If the dog becomes incontinent again, the dosage should be reverted to the previous one.
• Estradiol benzoate and diethylstilbestrol have been used in male dogs with some success, while androgens have yielded inconclusive results.

Sympathomimetic Drugs
• Sympathomimetic (α-agonistic) drugs, which directly stimulate α-adrenergic receptors in the bladder neck and urethra, are widely used and highly effective (75% to 90%). They show a quick onset of action (several days) and require twice-daily or, most commonly, 3-times-daily oral administration.
• Phenylpropanolamine and ephedrine are the most effective α-agonists for bitches and are also fairly effective for male dogs.
• Unlike estriol, the best dose regimen of sympathomimetic drugs starts low (1 mg/kg, Q 8-12 H) and is titrated up (<_3 mg/kg Q 8-12 H) until good efficacy is reached.

Anticholinergic Drugs
• Anticholinergic drugs are sometimes used, especially when detrusor instability (uncommon in the dog) is suspected or when sympathomimetic drugs are not effective. Cholinergic receptors mediate detrusor contraction as well as relaxation of the external urethral sphincter. Inhibiting their action facilitates bladder filling and prolongs the interval between voiding phases.
• Commonly used anticholinergics include propantheline (15 mg Q 8 H increasing to 30 mg Q 8 H) or oxybutinin (0.2 mg/kg Q 12 H increasing to Q 8 H).

GnRH Agonists
Gonadotropin-releasing hormone (GnRH) agonists such as leuprolide, buserelin, triptorelin, or deslorelin provide long periods of continence in approximately 50% to 60% of treated animals. A deslorelin implant often results in complete continence or decreased drug dependence. The oil-based implant dissolves over time and does not need to be removed at the end of the treatment period (6 or 12 months).

Contraindications/Precautions/Interactions
• No hematologic side effects in chronic toxicity studies have been observed using estriol for up to 3 months at daily doses > 3 mg/kg.
• Vulvar swelling and attractiveness to males are occasionally observed in bitches treated with high doses of estriol (2 to 3 mg/day).
• Side effects of α-agonists are rare and include anorexia, weight loss, increased excitability, restlessness, tachycardia, and skin eruption.
• Deslorelin implants have no side effects in dogs.

Nutritional Aspects
Incontinent animals, especially neutered adults, should get regular exercise and follow a strictly controlled diet to avoid becoming overweight.

Follow-Up

Patient Monitoring
No specific monitoring is necessary when the animal is continent. In case of a prolonged phase of UI, urinalysis should be performed to rule out cystitis. UI is often intermittent, so animals living outdoors should be periodically checked for signs of UI to identify phases of recurrence.

Complications
Chronic UI, especially if untreated, will lead to the development of UTI. Dogs undergoing surgery may show temporary dysuria.

Course
Resolution of UI usually takes less than a week both with medical and surgical approaches.

At-Home Treatment
Minimal care is typically required at home and includes administration of an estriol pill daily or a sympathomimetic oral solution 2 to 3 times a day.

In General

Relative Cost
Medication is relatively inexpensive ($), while the cost of surgery, if required, varies depending on the approach, length of time the patient is under anesthesia, and the number of days as an inpatient ($$$$$).

Prognosis
Prognosis is generally guarded to good, with full recovery occurring in approximately 60% of cases, improvement of the condition in approximately 30%, and no improvement in 10%, regardless of whether a medical or surgical approach is used.

Acknowledgment
The author wishes to thank Dr. Alessandro Zotti, University of Padua, Italy, for providing the figures in this article.

TX at a glance: see PDF


TREATMENT OF CANINE URINARY INCONTINENCE • Stefano Romagnoli

Suggested Reading
Association between urinary incontinence in bitches: Its incidence and relationship to neutering practices. Thrusfield MV. J Small Anim Pract 39:559-566, 1998.
Association in bitches between breed, size, neutering and docking, and acquired urinary incontinence due to urethral sphincter mechanism. Holt PE, Thrusfield MV. Vet Rec 133:177-180, 1993.
Clinical and radiographic findings compared with urodynamic findings in neutered female dogs with refractory urinary incontinence. Nickel RF, Vink-Noteboom M, Van der Brom WE. Vet Rec 145:11-15, 1999.
Clinical response and urethral pressure profile changes after phenylpropanolamine in dogs with primary sphincter incompetence. Richter KP, Ling GV. JAVMA 187:605-611, 1985.
Colposuspension. Holt PE, Stone EA. In Bojrab MJ (ed): Current Techniques in Small Animal Surgery, 4th ed -Philadelphia: Lippincott Williams & Wilkins, 1998, p 455.
Effect of a long acting GnRH analogue or placebo on plasma LH/FSH, urethral pressure profile and clinical signs of urinary incontinence due to sphincter mechanism incompetence in bitches. Reichler IM, Jochle W, Piché CA, et al. Theriogenology 66:1227-1236, 2006.
Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. Scott L, Leddy M, Bernay F, et al. J Small Anim Pract 43:493-496, 2002.
Long-term risks and benefits of early-age gonadectomy in dogs. Spain CV, Scarlett JM, Houpt KA. JAVMA 224:380-387, 2004.
Pelvic bladder in dogs without urinary incontinence. Mahaffey MB, Barsanti JA, Barber DL, et al. JAVMA 184:1477-1479, 1984.
Pharmacokinetics of oestriol after repeated oral administration to dogs. Hoeijmakers M, Janszen B, Coert A, et al. Res Vet Sci 75:55-59, 2003.
Treatment of bitches with acquired urinary incontinence with estriol. Mandigers PJI, Nell T. Vet Rec 149:764-767, 2001.
Treatment of urethral sphincter mechanism incompetence in 11 bitches with a sustained-release formulation of phenylpropanolamine hydrochloride. Bacon NJ, Oni O, White RAS. Vet Rec 151:373-376, 2002.
Treatment of urinary incontinence in bitches by endoscopic injection of glutaraldehyde cross-linked collagen. Arnold S, Hubler M, Lott-Stolz GH, et al. J Small Anim Pract 37:163-168, 1996.
Urethral sphincter mechanism incompetence in male dogs: A retrospective analysis of 54 cases. Aaron A, Eggleton K, Power C, Holt PE. Vet Rec 139:542-546, 1996.
Urinary incontinence in the bitch due to sphincter mechanism incompetence: Prevalence in referred dogs and retrospective analysis of 60 cases. Holt PE. J Small Anim Pract 26:181-190, 1985.
See also www.icsoffice.org, the official site of the International Continence Society (a society for the study of human incontinence).

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy